× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.

meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19  


COV-BARRIER , 2021   NCT04421027 2 weeks ago

baricitinib vs. placebo - COVID 19 hospitalized low risk of bias

  • suggested 43 % decrease in All-cause mortality at day 28
  • inconclusive results for: progression to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation (including ECMO), or death, by day 28


Conclusive (statistically conclusive): statistically demonstrated that is statistically significant with a strict control of overall risk of type 1 error, does not take into account the risk of bias; inconclusive: not nominally statistically significant; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error


This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.


- About - Our approach - Credits - RSS Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons